The chemical synthesis of testosterone marked a watershed moment in hormone replacement therapy, laying the groundwork for decades of clinical application. Testosterone exerts its biological effects primarily through binding to the androgen receptor (AR), a nuclear receptor that, upon activation, modulates gene transcription. Yet, the picture is far more complex. Testosterone is metabolized enzymatically by aromatase into 17β-estradiol, an estrogen receptor (ER) agonist, and converted by 5α-reductases into dihydrotestosterone (DHT), a more potent AR agonist incapable of aromatization. These metabolites broaden the spectrum of testosterone’s physiological impacts, enabling both genomic and rapid non-genomic signaling cascades.

Central to understanding testosterone’s systemic impact is its dualistic signaling. Genomic actions involve AR and ER-mediated modulation of target gene expression, a process that unfolds over hours to days, profoundly influencing cellular differentiation, proliferation, and metabolism. In parallel, testosterone and its derivatives can engage in non-genomic signaling, triggering rapid cellular responses through membrane-bound receptors and intracellular signaling pathways that influence ion fluxes, kinase activation, and second messenger systems. This combination of long- and short-term signaling mechanisms allows testosterone to fine-tune metabolic processes in a context-dependent fashion.

The metabolic roles of testosterone extend beyond reproductive tissues. In adipose tissue, testosterone influences lipolysis and adipogenesis, often opposing the accumulation of visceral fat associated with metabolic syndrome. It enhances insulin sensitivity in skeletal muscle, promoting glucose uptake and mitochondrial function. These anabolic effects contribute to the maintenance of lean body mass and overall metabolic vigor. Notably, testosterone deficiency correlates with increased risk of type 2 diabetes and cardiovascular diseases, underlining its importance in systemic metabolic health.

In females, testosterone serves equally vital metabolic functions, although these roles are less often emphasized in clinical discourse. The androgen receptor is expressed in multiple metabolic tissues, including liver, muscle, and adipose compartments, where testosterone modulates energy expenditure and substrate utilization. Emerging research indicates that perturbations in androgen signaling can contribute to metabolic dysfunctions observed in conditions such as polycystic ovary syndrome (PCOS), highlighting the hormone’s critical influence beyond reproductive physiology.

Therapeutically, testosterone replacement has traditionally been employed to treat hypogonadism and related symptoms. However, burgeoning data advocate for a broader therapeutic potential targeting metabolic derangements. Clinical trials suggest that testosterone supplementation can improve insulin sensitivity, reduce adiposity, and ameliorate lipid profiles, especially in hypogonadal men. Yet the balance is delicate; supraphysiological doses or inappropriate administration routes may exacerbate adverse outcomes, typifying the need for precision medicine approaches tailored to individual metabolic phenotypes.

At the molecular level, the interplay between testosterone and its metabolites with AR and ER subtypes orchestrates a symphony of metabolic gene regulation. The distinct but complementary actions of AR and ERα/β mediate tissue-specific responses, tuning metabolic pathways such as glycolysis, gluconeogenesis, and lipid biosynthesis. This coupling of androgenic and estrogenic signals illustrates the sophisticated endocrine crosstalk that testosterone navigates, offering a more integrated understanding of hormonal control over metabolism.

Preclinical models have been instrumental in delineating testosterone’s metabolic functions. Rodent studies reveal that androgen depletion leads to increased adiposity, insulin resistance, and impaired mitochondrial biogenesis, while restoration confers protective metabolic profiles. Genetically engineered models lacking AR or aromatase provide compelling evidence for the receptor-mediated mechanisms underlying these phenotypes, laying a mechanistic foundation for translating findings into human medicine.

In humans, observational studies fortify the link between endogenous testosterone levels and metabolic health indices. Lower testosterone concentrations associate with increased visceral fat, dyslipidemia, and impaired glucose handling. Conversely, physiological testosterone levels correspond with favorable metabolic parameters, underscoring the hormone’s role as a sentinel of metabolic integrity. However, age-associated declines complicate this relationship, prompting ongoing investigation into optimizing testosterone-based therapies in aging populations.

Advances in molecular endocrinology have also uncovered rapid, non-genomic actions of testosterone that modulate metabolic enzyme activity and hormone secretion. These effects occur within minutes, independent of gene transcription, and involve activation of kinase cascades such as MAPK and PI3K/AKT pathways. The non-genomic mechanisms contribute to acute regulation of insulin secretion, mitochondrial respiration, and nutrient uptake, highlighting an additional layer of metabolic control imparted by testosterone.

Clinical application of these insights demands a nuanced understanding of testosterone’s pleiotropic effects. The heterogeneity in androgen receptor polymorphisms, enzyme expression levels (e.g., aromatase and 5α-reductase), and tissue-specific receptor distribution necessitates personalized approaches to testosterone therapy. Future directions include selective androgen receptor modulators (SARMs) that aim to harness metabolic benefits while minimizing androgenic side effects, representing a promising frontier in metabolic disease intervention.

Moreover, the bidirectional relationship between testosterone and metabolism suggests feedback mechanisms whereby metabolic states influence androgen biosynthesis and signaling. Obesity and insulin resistance can suppress hypothalamic-pituitary-gonadal axis activity, leading to hypogonadism and further metabolic deterioration. This vicious cycle underscores the importance of integrated therapeutic strategies addressing both hormonal and metabolic dysfunctions simultaneously.

Testosterone’s role as a metabolic messenger also intersects with inflammatory pathways that underlie chronic metabolic diseases. Androgen signaling modulates immune cell function and inflammatory cytokine production, influencing the low-grade inflammation characteristic of obesity and type 2 diabetes. By tempering inflammatory responses, testosterone may confer protective effects beyond classical metabolic pathways, opening new avenues for research and therapy.

In sum, testosterone is emerging as a multifaceted metabolic regulator with far-reaching implications for both male and female physiology. Its intricate signaling networks span genomic and non-genomic domains, involving androgenic and estrogenic pathways that collectively orchestrate energy homeostasis. Appreciating these complex interrelations positions testosterone at the nexus of endocrine and metabolic health, with transformative potential for future clinical innovation.

As the landscape of metabolic research advances, re-evaluating testosterone’s role beyond reproduction holds transformative promise. Bridging basic science discoveries with clinical practice could foster the development of therapeutic interventions that leverage testosterone’s metabolic signaling to combat obesity, diabetes, and associated co-morbidities. This expanding horizon not only enriches our understanding of hormone biology but also underscores the importance of androgens as pivotal orchestrators of systemic metabolic resilience.

Subject of Research: Testosterone as a metabolic regulator and messenger.

Article Title: Metabolic Messengers: testosterone.

Article References: Mauvais-Jarvis, F., Bhasin, S. Metabolic Messengers: testosterone. Nat Metab (2026). https://doi.org/10.1038/s42255-025-01431-6

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s42255-025-01431-6

Prostate cancer remains one of the most pervasive malignancies affecting men globally. While initial treatment modalities often involve androgen deprivation therapy (ADT) to suppress AR signaling, many patients eventually progress to CRPC. This advanced stage of the disease is characterized by unabated tumor growth despite low circulating androgen levels, a resistance primarily attributed to the persistent activity of both full-length androgen receptors (AR-FL) and splice variants of AR (AR-Vs) that lack dependence on androgens. Understanding how these receptors sustain their activity in the absence of hormones is pivotal for developing next-generation targeted therapies.

The team’s study elucidates that a critical co-factor in sustaining AR activity is PCNA, a well-recognized DNA clamp that facilitates DNA replication and repair. Intriguingly, PCNA also interacts with AR, enabling efficient AR-mediated transcriptional activation. Through detailed biochemical studies, the researchers identified a second PCNA-interacting protein (PIP) box within the AR’s DNA binding domain, designated PIP-box592. This motif significantly enhances the binding affinity of AR-FL to PCNA, particularly when androgen dihydrotestosterone (DHT) is present, albeit such enhancement is absent in constitutively active AR splice variants like AR-V7.

Capitalizing on this discovery, Lu and Dong engineered a cell-permeable peptide, termed R9-AR-PIP, which mimics the identified PIP-box592 domain in AR, effectively acting as a decoy to disrupt the AR-PCNA interaction. Administering R9-AR-PIP to various prostate cancer cell lines, including androgen-dependent LNCaP cells and multiple CRPC cell lines expressing different AR isoforms, significantly reduced AR’s capacity to bind to DNA. This blockade resulted in a marked downregulation of AR target genes critical for cancer cell survival and proliferation.

Complementing the peptide approach, the researchers also evaluated a small molecule inhibitor, PCNA-I1S, known to impede PCNA’s nuclear translocation and its protein-protein interactions. Treatment with PCNA-I1S phenocopied the effects of R9-AR-PIP by attenuating AR activity and suppressing the proliferation of CRPC cells. These findings collectively support a dual modality to target the AR-PCNA axis, offering alternative therapeutic angles for intervention.

Among the most striking results was the observation that both R9-AR-PIP and PCNA-I1S treatments substantially diminished the levels of cyclin A2, a pivotal regulator of the S phase in the cell cycle. Cyclin A2 overexpression is commonly noted in aggressive prostate tumors and correlates with poor clinical outcomes. By curtailing cyclin A2, this therapeutic strategy not only impairs the proliferative capacity of tumor cells but also potentially sensitizes them to other therapeutic modalities.

The mechanistic underpinnings of these interventions reveal a nuanced interplay between androgen stimulation, AR structural domains, and PCNA co-factors. DHT’s ability to augment full-length AR’s interaction with PCNA hints at a complex regulation of AR activity that can be pharmacologically exploited. Meanwhile, the lack of DHT modulation for AR variants emphasizes the heterogeneity of CRPC and the necessity for multifaceted targeting strategies.

Importantly, this research addresses a longstanding challenge in CRPC therapeutics: the effective inhibition of AR splice variants that drive resistance to conventional anti-androgen therapies. By focusing on the conserved AR-PCNA interaction, the R9-AR-PIP peptide and PCNA-I1S small molecule provide promising avenues to overcome the limitations imposed by AR variant-driven resistance mechanisms.

The translational potential of these findings is significant. While current standards leverage androgen suppression and AR antagonists, the eventual emergence of resistant clones diminishes long-term efficacy. The inhibition of AR-PCNA interaction introduces a novel vulnerability, one that directly intersects with the molecular machinery protecting genomic integrity in tumor cells. This dual impact on transcriptional regulation and DNA replication stress may culminate in synthetic lethality, selectively eliminating cancer cells.

Looking forward, the authors emphasize the importance of validating these findings in in vivo models and clinical settings. The pharmacodynamics, bioavailability, and potential off-target effects of these agents warrant rigorous examination. Nonetheless, the study opens vistas for developing combinatorial regimens wherein AR-PCNA interaction inhibitors are combined with existing therapies to delay or prevent the onset of resistance.

Furthermore, this work enriches the broader understanding of how non-traditional functions of DNA repair proteins can be co-opted by oncogenic signaling pathways. PCNA, classically confined to replication and repair, is emerging as a multifunctional scaffold modulating transcription factor activity. Such insights may pave the way for analogous strategies in other malignancies where similar protein interactions drive disease progression.

The implications for personalized medicine are profound. Identifying patients with tumors heavily reliant on AR-PCNA interactions could inform stratified therapeutic approaches, leveraging peptide or small molecule inhibitors tailored to individual molecular profiles. This precision oncology paradigm underscores the necessity of integrating molecular diagnostics with therapeutic innovation.

In summary, the study by Lu and Dong constitutes a seminal step toward the development of innovative therapeutics in castration-resistant prostate cancer. By targeting the AR-PCNA interface—a hitherto underexplored axis—they offer hope for improved outcomes in a patient population with notoriously limited options. As this research progresses from bench to bedside, it represents a promising beacon in the fight against lethal prostate cancer.

Subject of Research: Cells

Article Title: Targeting PCNA/AR interaction inhibits AR-mediated signaling in castration resistant prostate cancer cells

News Publication Date: 20-May-2025

Web References:

• Journal: Oncotarget
• DOI: 10.18632/oncotarget.28722

Image Credits: Copyright: © 2025 Lu and Dong. Distributed under the Creative Commons Attribution License (CC BY 4.0).

Keywords: cancer, PCNA, androgen receptor, PCNA inhibitors, AR splicing variants, CRPC